ArticleACS omega2026
Cocrystal Formation of Quercetin and Nutraceutical Coformers via a Facile Technique with Improved Solubility and Biological Properties.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cocrystallization has emerged as an effective strategy to improve the physicochemical and pharmaceutical properties of bioactive compounds. Here, we prepared novel cocrystals of quercetin (Que) and nutraceutical coformers, i.e., vitamin B6, inositol and l-carnitine, by using slurry methods. The cocrystals were characterized using orthogonal techniques, including scanning electron microscopy (SEM), powder X-ray diffraction (PXRD), DSC, Fourier transform infrared (FTIR) spectroscopy, and X-ray photoelectron spectroscopy (XPS), providing complementary insights into the morphology, crystallinity, thermal behavior, and molecular interactions and confirming the formation of distinct solid phases. Dissolution studies revealed markedly enhanced solubility and release rates up to 1.2-2.5-fold higher within the first hour compared to unmodified quercetin. In cell-based assays, all cocrystals exhibited improved cytotoxicity against cervical and lung cancer cells via apoptotic induction and effective ROS reduction while maintaining minimal toxicity toward normal cells. Among all cocrystals, the cocrystal between quercetin and l-carnitine (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.